for listing of our common stock on the NASDAQ Global Market under the symbol “HSGX.” We expect that the public offering price will be between $13.00 and $15.00 per share.We are an “emerging growth company” under applicable Securities and Exchange Commission rules and will be subject to reduced public company reporting requirements for this prospectus and future filings.Our business and an investment in our common stock involve significant risks.
we fail to obtain, or if we experience a delay in obtaining such approval, our business, operating results and prospects will be adversely affected.We believe our regenerative medicine platform may provide us with the ability to develop a strong pipeline, and that the positive clinical data we have seen in treating cartilage damage of the knee with
We believe this arrangement will enable us to develop potential next-generation cartilage products, increase our future manufacturing capacities and efficiencies, and accelerate our platform technology pipeline initiatives.Risks Related to Our BusinessOur business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of
commercialize NeoCart, or experience significant delays due to manufacturing or otherwise in doing so, our business will be materially harmed.•The technologies on which our channel partnering agreement with Intrexon is based are currently in preclinical and clinical stages of development.•We will incur additional expenses in connection with our exclusive channel collaboration agreement with Intrexon.•We may experience delays in commencing or conducting our clinical trials or in receiving data from third parties or in the completion of clinical
testing, which could result in increased costs to us and delay our ability to generate product candidate revenue.•If we fail to complete clinical trials and obtain regulatory approval for NeoCart, our business would be significantly harmed.•Our clinical development of NeoCart could be substantially delayed if the FDA requires us to conduct additional studies or trials or imposes other
follows:•Approximately $16.0 million to fund, develop and advance NeoCart through our currently enrolling Phase 3 clinical trial;•Approximately $2.9 million for development work associated with our Exclusive Channel Collaboration Agreement with Intrexon;•Approximately $5.1 million to build out our manufacturing capabilities and develop potential process improvements in making NeoCart; and•The remainder for general and administrative expenses (including personnel-related costs), potential future development programs, early-stage research
which no awards will be granted prior to the effective date of the registration statement of which this prospectus is a part, subject to automatic annual adjustment in accordance with the terms of the plan.Unless otherwise indicated, this prospectus includes and assumes the following, each to occur upon completion of this offering:•721,448 shares issuable upon the automatic conversion of a convertible promissory note in the principal amount of $10.0 million held by Intrexon,
(FDA) as to the comparability of such raw materials to those manufactured by third parties for use in our NeoCart clinical trials;•obtain required regulatory approvals for the commercialization of NeoCart;•manage our spending as costs and expenses increase due to clinical trials, regulatory approvals, manufacturing and commercialization;•continue to build and maintain a strong intellectual property portfolio;•build and maintain appropriate research and development, clinical, sales, manufacturing, financial reporting, distribution and marketing capabilities
on our own or through third parties;•secure additional funding as may be needed;•gain broad market acceptance for our product candidates; and•develop and maintain successful strategic relationships.If we are unsuccessful in accomplishing any of these objectives, we may not be able to develop product candidates, raise capital, expand our business or continue our operations.10Table of ContentsWe have incurred significant losses since our inception and anticipate that we will continue to incur
Our ability to successfully commercialize NeoCart will depend, among other things, on our ability to:•successfully complete our clinical trials;•produce, through a validated process, NeoCart in quantities sufficiently large to permit successful commercialization;•receive marketing approvals from the FDA and similar foreign regulatory authorities;•launch commercial sales of NeoCart; and•secure acceptance of NeoCart in the medical community and with third-party payors.NeoCart and our future product candidates are subject to extensive regulation, compliance with which is costly and time consuming, may cause
trial work, including the ongoing NeoCart Phase 3 clinical trial, according to our current projected timelines, and the FDA may delay approval of the new raw material source or require additional studies to show comparability.•We may not achieve our anticipated production throughput targets, resulting in lower than anticipated capacity, limiting supply of our products,
foregoing reasons, or for any other reason, it could affect our sales, having an adverse effect on our business, financial condition and results of operations.We will need additional capital to develop and commercialize our product candidates including NeoCart, and we may be unable to raise additional capital when needed at all, which could force us to
factors, including:•the type, number, costs and results of the product candidate development programs which we are pursuing or may choose to pursue in the future;•the scope, progress, expansion, costs and results of our preclinical and clinical trials;•the timing of and costs involved in obtaining regulatory approvals;•market acceptance of any products for which we receive approval;•our ability to establish and maintain development partnering arrangements;•the timing, receipt and amount of contingent, royalty and other payments from our future development partners, if any;•the emergence of competing technologies and other adverse market developments;•the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and liabilities;•the resources we devote to marketing and, if approved, commercializing our product candidates;•the scope, progress, expansion and costs of manufacturing our product candidates; and•the costs of financing the purchases of additional capital equipment and development technologies.If we are unable to raise additional funding for our product candidates, including NeoCart, when needed, we may be required to delay, reduce or terminate
things:•the results of our and our collaborative partners’ preclinical studies and clinical trials;•our ability to recruit and enroll patients for our clinical trials;•the efficacy, safety and reliability of our product candidates;•the speed at which we develop our product candidates;•our ability to design and successfully execute appropriate clinical trials;•our ability to protect and develop intellectual property rights related to our products;•our ability to maintain a good relationship with regulatory authorities;•the timing and scope of regulatory approvals, if any;•our ability to commercialize and market any of our product candidates that receive regulatory approval;•market perception and acceptance of regenerative medicine products;•acceptance of our product candidates by physicians, patients and institutions;•the price of our products;•adequate levels of reimbursement under private and governmental health insurance plans, including Medicare; and•our ability to manufacture and sell commercial quantities of any approved products to the market.If our competitors market products that are more effective, safer or less expensive than our future products or that reach the market sooner than our
we:•successfully attract and recruit new employees or consultants with the requisite expertise and experience;•manage our preclinical and clinical programs effectively;28Table of Contents•develop a marketing and sales infrastructure if we receive regulatory approval for any product candidate;•continue to improve our operational, financial and management controls, reporting systems and procedures, including those related to being a public